Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor + albumin paclitaxel + bevacizumab for first-line treatment of relapsed or metastatic triple negative breast cancer
ChiCTR2200058567Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of nab-paclitaxel and bevacizumab in breast cancer (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Jun 2021; status: recruiting.
02
Drugs
nab-paclitaxelbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200058567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058567.